Skip to content

Docetaxol plus carboplatin VS. 5-FU plus carboplatin induction chemotherapy and carboplatin concurrent chemoradiotherapy in local-ragionally advanced nasopharyngeal carcinoma

Docetaxol plus carboplatin VS. 5-FU plus carboplatin induction chemotherapy and carboplatin concurrent chemoradiotherapy in local-ragionally advanced nasopharyngeal carcinoma

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002626
Enrollment
Unknown
Registered
2012-01-08
Start date
2005-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Interventions

A:Docetaxol plus carboplatin induction chemotherapy
B:Docetaxol plus carboplatin induction chemotherapy

Sponsors

Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Histologic diagnosis of nasopharyngeal carcinoma; 2. Aged between 18 and 60 years; 3. T3N0-2M0, T4N0-2M0, T1-4N2M0(UICC 2002 edition); 4. KPS>=80; 5. No distant metastasis; 6. WBC count>=4*10^9/L, Hemoglobin>=100g/L, platelet count>=100*10^9/L; 7. ALT or AST<2*ULN, bilirubin<1.5*ULN; 8. Serum creatinine<1.5*ULN.

Exclusion criteria

Exclusion criteria: 1. Distant metastases; 2. Previously treated (surgery, chemotherapy, radiotherapy, EGFR targeted therapy or immunotherapy); 3. Second malignancy within 5 years; 4. Precious therapy with an investigational agent; 5. Uncontrolled seizure disorder or other serious neurologic disease; 6. Allergic reaction (>=Grade III) to any drug including in this study; 7. Clinically significant cardiac or respiratory disease; 8. Creatinine clearance <30ml/min; 9. Drug or alcohol addiction; 10. Do not have full capacity for civil acts; 11. With severe complications or active infection; 12. Concurrent immunotherapy or hormone therapy for other diseases; 13. Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
failure free survival rate;overall survival rate;locoregional failure free survival rate;disease free survival rate;distant metastasis free survival rate;quality of lif;

Contacts

Public ContactXiang Yanqun
xiangyq@sysucc.org.cn+86 020-87343359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026